IP Library Granted Patent US 8,623,412
Granted Patent B2
US 8,623,412 · App. 10/528,727 · Granted Jan 7, 2014

Abuse-resistant pharmaceutical compositions

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,623,412
App. No.
10/528,727
Granted
Jan 7, 2014
Kind
B2
Abstract

An abuse-resistant controlled release pharmaceutical composition comprising a pharmaceutically effective amount of discrete particles of an active capable of abuse, wherein surfaces of said particles are wetted with a water insoluble coating material, and preferably wherein said composition comprises a matrix, in which said particles are distributed, and which renders the abuse-capable compound within the matrix difficult to separate from the matrix; and a method for the preparation of a controlled release pharmaceutical composition having a reduced potential for abuse, comprising applying a pressure force to a mixture comprising a water insoluble material, and particles of a pharmaceutically active compound capable of inducing in a subject a reaction that is physiologically or psychologically detrimental if administered in an immediate release dosage form, thereby resulting in surface coated particles, and incorporating said surface coated particles into a pharmaceutical composition.

Claims (12)

1. An abuse-resistant controlled-release pharmaceutical composition comprising a plurality of microspheres, each microsphere comprises:

(i) a water insoluble matrix material, and

(ii) a plurality of discrete particles distributed throughout the water insoluble matrix material, each particle comprises a pharmaceutically effective amount of an active water soluble compound capable of abuse and having surfaces that are wetted with a coating of the water insoluble matrix material,

wherein said water insoluble matrix material is present in an abuse-reducing amount whereby crushing, compressing, fracturing, tumbling, rolling, or milling of said controlled-release pharmaceutical composition results in an increase in the aqueous dissolution of said active water soluble compound by less than about 15% of the total pharmaceutically effective amount of the active water soluble compound in the composition in the first hour of in vitro dissolution testing,

wherein the water soluble compound capable of abuse is an opioid agonist, and

wherein the composition does not include an antagonist of the water soluble compound capable of abuse.

2. The abuse-resistant composition according to claim 1 wherein said matrix material is non-erodable at pH less than about 6.

3. The abuse-resistant composition according to claim 2 wherein said matrix material is erodable in the presence of bile salts and lipase.

4. The abuse-resistant composition according to claim 1 wherein crushing said matrix before contacting with water increases the aqueous dissolution of active water soluble compound in said composition by less than about 10% of the total pharmaceutically effective amount of the active water soluble compound in the composition in the first hour of in vitro dissolution testing.

5. The abuse-resistant controlled-release pharmaceutical composition according to claim 1 for administration to a subject in need thereof from once to four times a day.

6. The dosage form according to claim 1 wherein said opioid agonist is selected from the group consisting of fentanyl, sufentanil, carfentanil, lofentanil, alfentanil, hydromorphone, oxycodone, hydroxycodone, propoxyphene, methadone, tilidine, butorphanol, buprenorphine, levorphanol, codeine, oxymorphone, meperidine, dihydrocodeinone and cocaine.

7. The abuse-resistant composition of claim 1 , wherein the matrix material is a triglyceride wax selected from the group consisting of a hydrogenated cottonseed oil wax, a partially hydrogenated soybean oil, carnuba wax or a mixture thereof.

Assignments (11)
RELEASE OF SECURITY INTEREST IN PATENTS PREVIOUSLY RECORDED AT REEL/FRAME (073213/0302) Recorded Feb 13, 2026
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: ALKERMES PHARMA IRELAND LIMITED
Reel/Frame 074858/0429 →
SECURITY INTEREST Recorded Oct 23, 2025
From: ALKERMES PHARMA IRELAND LIMITED
To: JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT
Reel/Frame 073213/0302 →
RELEASE OF PATENT SECURITY AGREEMENT (FIRST LIEN) Recorded Dec 24, 2024
From: MORGAN STANLEY SENIOR FUNDING, INC.
To: ALKERMES, INC.; ALKERMES PHARMA IRELAND LIMITED
Reel/Frame 069771/0548 →
RELEASE BY SECURED PARTY (SECOND LIEN) Recorded Oct 12, 2012
From: MORGAN STANLEY SENIOR FUNDING, INC.
To: ALKERMES, INC.; ALKERMES PHARMA IRELAND LIMITED; ALKERMES CONTROLLED THERAPEUTICS INC.
Reel/Frame 029116/0379 →
PATENT SECURITY AGREEMENT (FIRST LIEN) Recorded Sep 29, 2011
From: ALKERMES, INC.; ALKERMES PHARMA IRELAND LIMITED; ALKERMES CONTROLLED THERAPEUTICS INC.
To: MORGAN STANLEY SENIOR FUNDING, INC.
Reel/Frame 026994/0186 →
PATENT SECURITY AGREEMENT (SECOND LIEN) Recorded Sep 29, 2011
From: ALKERMES, INC.; ALKERMES PHARMA IRELAND LIMITED; ALKERMES CONTROLLED THERAPEUTICS INC.
To: MORGAN STANLEY SENIOR FUNDING, INC.
Reel/Frame 026994/0245 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 20, 2010
From: VERION INCORPORATED
To: ELAN PHARMA INTERNATIONAL LIMITED
Reel/Frame 025010/0515 →
CONFIRMATORY ASSIGNMENT Recorded Mar 8, 2010
From: LIVERSIDGE, GARY; RUDDY, STEPHEN B.
To: ELAN CORPORATION, PLC
Reel/Frame 024041/0155 →
EMPLOYMENT AGREEMENT Recorded Jul 29, 2009
From: VAGHEFI, FARID
To: DELTA FOOD GROUP INC.
Reel/Frame 023160/0187 →
CHANGE OF NAME Recorded Jul 29, 2009
From: DELTA FOOD GROUP INC.
To: VERION INCORPORATED
Reel/Frame 023023/0415 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 23, 2008
From: ELAN CORPORATION, PLC
To: ELAN PHARMA INTERNATIONAL LIMITED
Reel/Frame 021279/0892 →